FibroGen has developed the only commercially viable method known to produce human collagen and human gelatin in recombinant systems. FibroGen will exploit this technology by becoming both a bulk product supplier for the pharmaceutical and medical device industries as well as a developer and commercializer of injectable products, wound management products, and gelatin stabilizers. FibroGen's corporate collaborations include a partnership with Taisho Pharmaceutical Company of Japan to discover and develop human monoclonal antibody therapeutics for renal fibrosis and chronic transplant rejection.

South San Francisco, California

First Horizon Pharmaceutical Corporation is a specialty pharmaceutical Company that markets prescription products in four therapeutic areas: cardiology, obstetrics and gynecology, pediatrics and gastroenterology. The Company has a portfolio that includes 17 branded prescription products of which 7 are actively promoted to high-prescribing physicians through its nationwide marketing and sales force.

Alpharetta, Georgia

Fujisawa Healthcare, Inc., headquartered in Deerfield, Illinois is a subsidiary of Fujisawa Pharmaceutical Company, Ltd., based in Osaka, Japan. Fujisawa Pharmaceutical Co., Ltd., founded in 1894, is a leading pharmaceutical manufacturer and is actively developing its international operations in North America, Europe and Asia. Being the world's largest pharmaceutical market, the United States naturally occupies a preeminent position at the core of Fujisawa's international strategy.

Fujisawa Pharmaceuticals merged with Yamanouchi Pharmaceuticals in April 2005 to become Astellas Pharma Inc.

Deerfield, Illinois

GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialysis patients. In addition, WelChol(TM) brand colesevelam hydrochloride was granted marketing approval by the FDA in May 2000, for the treatment of hypercholesterolemia, a condition characterized by undesirably high blood cholesterol levels. (WelChol is a trademark of Sankyo Pharma Inc., our partner for commercializing WelChol)

Waltham, Massachusetts

GEN-PROBE currently markets several product lines, including the PACE® 2 System, the GEN-PROBE® AMPLIFIED™ Direct Tests, and the AccuProbe® System. Other products are currently under development or awaiting FDA approval. GEN-PROBE products continue to set the standard for DNA probe technology in the diagnostic industry, with assays for sexually transmitted diseases, microbial infectious diseases, and culture identification. In addition, we offer a full line of supporting instrumentation.

San Diego, California

Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Research and development efforts are focused on anti-angiogenesis and respiratory diseases. Genaera has three products in development addressing substantial unmet medical needs in major pharmaceutical markets. These include squalamine, an anti-angiogenic treatment for eye disease and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.

5110 Campus Drive
Plymouth Meeting, Pennsylvania 19462
  (610) 941-4020
  info@genaera.com

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA-based diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies.

Five Science Park
New Haven, Connecticut 06511
  203.773.1450
  info@genaissance.com

Genentech, Inc. Genentech, the founder of the biotechnology industry, is a company with a quarter-century track record of delivering on the promise of biotechnology. Today, Genentech is among the world's leading biotech companies -- with 10 protein-based products on the market for serious or life-threatening medical conditions. Genentech's product pipeline includes approximately 20 projects that focus primarily on oncology, cardiovascular disease and immunological disease. With its world-renowned research organization, unparalleled development and manufacturing capabilities, highly sophisticated commercial organization, and close to 5,000 competent, creative and enthusiastic employees, Genentech continues to transform the possibilities of biotechnology into improved realities for patients. For more general information about the company, visit our corporate overview section.

South San Francisco, California

Genesis Bio-Pharmaceuticals was established in 1990 as a Pharmaceutical marketing and distribution organization specializing in providing plasma derivative products, transplant products, vaccines and specialty surgical products as well as unique distribution services to hospitals, clinics, home IV therapy centers, pharmacies and physician offices. Genesis Bio-Pharmaceuticals has relationships with most major plasma derivative manufacturers as well as with many other vaccine and specialty pharmaceutical product organizations.

Hackensack, New Jersey

Genetronics Biomedical Corporation is a leader in electroporation therapy with 216 patents issued, allowed, or pending. The Company utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, vaccines, and gene therapy. In oncology, Genetronics has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer. In gene therapy, Genetronics has several collaborations with major biotechnology and pharmaceutical companies for the delivery of therapeutic genes or vaccines using electroporation. Genetronics' BTX Division, a leader in molecular delivery, features electroporation and electro fusion technology for research laboratory markets worldwide.

San Diego, California

Geneva Pharmaceuticals is one of the leading generic pharmaceutical manufacturers and marketers in the United States. Recent acquisitions of Invamed (now called Geneva Pharmaceuticals Technology Corporation, or GPTC) and the marketing rights to Apothecon’s anti-infective and generic product lines have strengthened our position as a market leader.

Broomfield, Colorado

GenoMed is a Next Generation Disease Management (tm) company that uses medical genomics to improve patient outcomes. GenoMed is working to translate knowledge of medical genomics (the study of which genes cause disease) into clinical practice: developing better drugs, using existing drugs for new indications, and identifying diseases before symptoms arise. By studying disease genes, we hope to make medicine less invasive and more proactive.

St. Louis, Missouri

Genta is a biopharmaceutical company that identifies, develops, and commercializes drugs for the treatment of patients with cancer. We market drugs to a physician-centered healthcare system. Employees and shareholders are rewarded by a corporate culture that values excellence in performance, innovation, quality, leadership and absolute integrity. Genta"s rich pipeline is anchored by 4 key components: ;Antisense Technology; Androgenics Products; Gallium Products; and Decoy Aptamers. The products from each of these platforms address significant unmet medical needs, in markets that individually exceed $1 billion dollars annually. The Company"s lead antisense compound, GenasenseTM, is currently in late-stage clinical trials for treatment of melanoma, multiple myeloma, chronic lymphocytic leukemia and non-small cell lung cancer.

Two Connell Drive
Berkeley Heights, New Jersey 07922
  908-286-3980
  info@genta.com

GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an exciting product portfolio, which includes TNFerade™ for the treatment of cancer and BIOBYPASS® angiogen for the treatment of cardiovascular disease.

Gaithersburg, Maryland

Genzyme Biosurgery (Nasdaq: GZBX) develops and commercializes implantable biotechnology products. It is focused on three medical areas - orthopaedic disease and injury, serious heart disease, and improving the outcomes of surgery. Within these areas, our portfolio includes a range of marketed biotherapeutics, biomaterials and medical devices, with many more in the pipeline.

Cambridge, Massachusetts

Genzyme General, one of the three divisions of Genzyme Corporation, develops and commercializes innovative solutions for major unmet medical needs of patients with genetic and serious debilitating diseases. Genzyme General is composed of five operating units: Genzyme Therapeutics, Genzyme Genetics, Genzyme Diagnostics and Genzyme Pharmaceuticals.

Cambridge, Massachusetts

Genzyme Molecular Oncology (Nasdaq: GZMO) is positioned where the power and promise of genomics and biotechnology meet. It is utilizing its powerful proprietary functional genomics and antigen discovery technology platforms to develop novel cancer products and to create a deep and promising product pipeline focused on cancer vaccines and angiogenesis inhibitors. It is shaping these new therapies through the integration of its genomics, gene and cell therapy, small-molecule drug discovery, and protein therapeutic capabilities.

Cambridge, Massachusetts

At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs focus on nucleotides, liposomes, durable HIV inhibitors and other small molecules. To date, Gilead's portfolio includes six marketed products and several clinical and preclinical products in development.

Foster City, California

Glades Pharmaceuticals is the generic division of Stiefel Laboratories, a company focusing specifically on products for the skin since its inception in 1847. Being part of the world’s leading dermatology company has helped Glades grow quickly since we launched our first product in 1991. Glades is now the leading dermatology-only generic company with a variety of topical steroids, acne drugs, antibiotics, skin bleaches, and OTC’s.

Suwanee, Georgia

GlaxoSmithKline GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.

Brentford, Middlesex, United Kingdom

Gliatech Inc. is engaged in the discovery and development of biosurgery and pharmaceutical products. The biosurgery products include ADCON(R) Gel (ADCON(R)-L & T/N) and ADCON(R) Solution, which are biopolymer medical devices designed to inhibit scarring and adhesions following surgery. Gliatech's pharmaceutical product candidates include proprietary monoclonal antibodies designed to inhibit inflammation.

Cleveland, Ohio

Global Pharmaceuticals is the generics marketing division of IMPAX Laboratories, Inc., a technology-based specialty pharmaceutical company applying its formulation expertise and drug-delivery technology to the development of controlled-release and niche products. Global’s multi-source product line consists of a growing range of solid oral prescription pharmaceuticals, distributed primarily through drug wholesalers, distributors, warehousing chains, and managed healthcare organizations.

Philadelphia, Pennsylvania

GlycoGenesys, Inc. is a biotechnology company developing novel drug candidates primarily based on glycobiology. Our product development strategy focuses on therapeutic applications where there is an unmet medical need for life threatening or debilitating diseases. The company's lead drug candidate, GCS-100, formerly known as GBC-590, is a potential treatment for multiple forms of cancer.

Boston, Massachusetts

Guilford Pharmaceuticals Inc. was founded in July 1993 by Scios Nova Inc., Dr. Solomon H. Snyder and Dr. Craig R. Smith to discover and develop novel pharmaceutical and biopolymer-based products that are intended to offer new and better treatments for serious medical conditions like Parkinson's disease, Alzheimer's disease, cancer and diabetic peripheral neuropathy. To focus its efforts, the company has developed two innovative technology platforms that have already spawned one commercial product and more than half a dozen novel product candidates.

Baltimore, Maryland

Gynétics' first major product was the PREVEN™ Emergency Contraceptive Kit, which was introduced in September, 1998. The original package has been supplemented with the addition of the PREVEN™ Emergency Contraceptive Pills package in May 2000. Gynétics also markets the GynoSampler® Endometrial Curette, a diagnostic endometrial tool that plays an increasingly important role within the in-office diagnostic environment. Endometrial sampling should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal uterine bleeding and as surveillance of all women taking estrogen as part of hormone replacement therapy.


Hoffmann-La Roche Inc. is the U.S. prescription drug unit of the Roche Group, a leading international health care company with principal businesses in pharmaceuticals, diagnostics and vitamins. Roche provides more than 35 medications in the United States in major therapeutic areas including AIDS, cardiovascular diseases, central nervous system disorders, dermatology, infectious diseases, oncology and transplantation.

Nutley, New Jersey

Hyseq Pharmaceuticals, Inc. is engaged in research and development of novel biopharmaceutical products from its collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. This platform provided a significant advantage in discovering novel, rarely-expressed genes, and assembly of one of the most important proprietary databases of full-length human gene sequences. Hyseq intends to further elucidate the physiological roles of its proprietary novel genes. Hyseq's database includes genes which encode a number of therapeutically important classes of molecules including chemokines, growth factors, stem cell factors, interferons, integrins, proteases, hormones, receptors, and other potential protein therapeutics or drug targets.

Sunnyvale, California

IGEN develops and markets biological detection systems based on its proprietary ORIGEN technology, which provides a unique combination of sensitivity, reliability, speed and flexibility. ORIGEN-based systems are used in a wide variety of applications, including clinical diagnostics, pharmaceutical research and development, life science research, biodefense testing and testing for food safety and quality control. These systems are marketed globally by IGEN and its licensees and/or distributors. Merger with Roche completed 2/13/2004.

16020 Industrial Drive
Gaithersburg, Maryland
  301-869-9800

igeneon is a biopharmaceutical company which focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin. It has built up a well balanced portfolio of cancer immunotherapies. The three key products, which are broadly applicable, are undergoing clinical trials up to Phase II/III. A number of innovative follow-up projects are also in the pipeline. igeneon is privately financed. Investors include 3i, Novartis Venture Fund and Deutsche Venture Capital.

Vienna, Austria
  +43-1-90 250
  ursula.mayer@igeneon.com

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments, designed to address the medical needs of patients with a variety of cancers. The Company's three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Somerville, New Jersey.

New York, New York
  media@imclone.com

ImmunoGen, Inc. (Nasdaq: IMGN) develops innovative biopharmaceuticals for the treatment of cancer. The Company's proprietary TAP technology combines extremely potent, cell-killing agents with monoclonal antibodies that recognize and bind specifically to tumor cells. This targeted delivery technology increases the potency of these cancer-specific antibodies, which allows the drugs to kill cancer cells with minimal harm to healthy tissue. ImmunoGen’s TAP technology is designed to address the two fundamental limitations associated with traditional chemotherapeutics: efficacy and tolerability.

Cambridge, Massachusetts

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division.

Hayward, California

Incara Pharmaceuticals Corporation is focused on a new class of disease-modifying small molecules, the catalytic antioxidants. Oxygen derived free radicals are a common step in neuronal death resulting from a variety of causes. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurologic disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease) and stroke and in other non-neurological indications such as cancer radiation therapy, chronic bronchitis and asthma.

4401 Research Commons, Ste 200
Research Triangle Park, North Carolina 27709
  919-558-8688
  info@incara.com

Incyte Corporation Incyte is a Wilmington, Delaware-based drug discovery and development company with a growing pipeline of novel small molecule drugs to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset, is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. Currently, Incyte has four drug discovery programs underway, an extensive intellectual property portfolio and a proteomic information business based in Beverly, Massachusetts.

Wilmington, Delaware

Innapharma, Inc. is engaged in the development of a series of "small chain" peptide-based products to treat central nervous system disorders, with the Company's leading product being an antidepressant. Innapharma also has a series of new tetracycline molecules in early development. These molecules may have activity against certain cancers and rheumatoid arthritis, in addition to antibiotic activity. Initial testing has already provided encouraging results in pre-clinical models.

Park Ridge, New Jersey

Integrity Pharmaceutical's prescription products treat lower urinary tract pain and spasms; and provide women in childbearing years optimal prenatal nutrition. Our generic drugs are valuable for patients and health care providers because they represent high quality, low cost alternatives to many of today's commonly prescribed medications.

Fishers, Indiana

InterMune is a commercially driven biopharmaceutical company focused on the marketing, development and applied research of life-saving therapies for pulmonary disease, infectious disease and cancer. We market three products: Actimmune® (Interferon gamma-1b), Infergen® (Interferon alfacon-1), and Amphotec® (Amphotericin B Cholesteryl Sulfate Complex for Injection), and have a late-stage development pipeline including 15 active clinical trials. Our lead clinical programs are focused on developing Actimmune for idiopathic pulmonary fibrosis, ovarian cancer and liver fibrosis; developing oritavancin as a novel antibiotic for the treatment of serious Gram-positive infections and developing a pegylated form of Infergen (PEG-Infergen) for chronic hepatitis C infections.

Brisbane, California

Introgen Therapeutics is a leader in the development and production of gene-based drugs for the treatment of cancer and other diseases.

Austin, Texas

Inverness Medical Innovations manufactures and sells products for the women’s health and nutritional product markets and is engaged in the business of developing, acquiring, manufacturing, and marketing advanced medical device technologies. The Company’s women’s health and nutritional products are distributed to consumers through established retail distribution networks such as Wal-Mart, Walgreens and CVS.

Waltham, Massachusetts

Invitrogen Corporation develops, manufactures and markets research tools in kit form for biotechnology researchers and companies worldwide. Our goal is to assist life scientists in accomplishing biological procedures faster, more reliably and in a more cost effective manner. We offer thousands of products and services that simplify and improve gene cloning, gene expression, and gene analysis techniques for corporate, academic and government entities.

Carlsbad, California

IVAX Pharmaceuticals, Inc develops, manufactures, and markets brand equivalent (generic) pharmaceutical products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home providers, and government agencies in the United States. IVAX Pharmaceuticals is a subsidiary of Miami-based IVAX Corporation, which is engaged in the research, development, manufacture, and marketing of branded and brand equivalent pharmaceuticals worldwide. IVAX Pharmaceuticals is one of the premier brand equivalent drug companies in the U.S., with an estimated 6% of the domestic market. IVAX Pharmaceuticals offers a balanced product portfolio featuring specialty generics and a broad range of other brand equivalent products that meet the needs of its customers. Under the "IVAX Pharmaceuticals" and "Goldline" trade names, IVAX Pharmaceuticals manufactures and markets approximately 50 brand equivalent prescription drugs in capsule or tablet forms in an aggregate of approximately 120 dosage strengths.

Miami, Florida

Janssen Pharmaceutica Products, L.P., is a company driven by a dedication to product innovation, customer focus and employee/organizational excellence. In the United States, medications now available in pharmacies include drugs for the treatment of psychotic disorders, such as schizophrenia; mild to moderate Alzheimer's disease; chronic pain; fungal infections; erosive gastroesophageal reflux disease (GERD); and duodenal ulcers. Janssen is proud to be a member of the Johnson & Johnson family of companies.

Titusville, New Jersey

Johnson & Johnson Johnson & Johnson, with approximately 104,500 employees, is the world's most comprehensive and broadly-based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical and medical devices and diagnostics markets. Johnson & Johnson has more than 197 operating companies in 54 countries around the world, selling products in more than 175 countries.

New Brunswick, New Jersey

RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.